AstraZeneca dosed its first participants in a phase 1 trial of its investigational monoclonal antibody product AZD7442 for preventing and treating COVID-19.

The trial will evaluate the safety, tolerability and pharmacokinetics of the treatment in up to 48 healthy participants ages 18 to 55 years old in the United Kingdom.

AZD7442 is a combination of two monoclonal antibodies that were discovered by researchers at Vanderbilt University Medical Center and licensed to AstraZeneca in June.